

**CLINICAL RESEARCH IN INFECTIOUS DISEASES**

**SAFETY SUMMARY REPORT**

**Prepared for the Safety Monitoring Committee**

**for**

**DMID Protocol 20-0003:**

**Phase I, Open-Label, Dose-Ranging Study of the Safety and  
Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy  
Adults**

**APPENDICES - REDACTED**

02 JUNE 2020

Prepared and distributed by:  
Statistical and Data Coordinating Center (SDCC)  
Emmes  
Rockville, Maryland

THIS COMMUNICATION IS PRIVILEGED AND CONFIDENTIAL

## TABLE OF CONTENTS

APPENDIX A: Adverse Event Definitions .....	2
APPENDIX B: Listing of Non-Serious, Unsolicited, Moderate or Mild, or Severe Adverse Events .....	5
APPENDIX C1: Solicited Systemic Events.....	30
APPENDIX C2: Solicited Local Events .....	166
APPENDIX D: Attribution for Systemic Solicited Events that Contribute to Halting Criteria .....	301
APPENDIX E: Listing of Abnormal Clinical Laboratory Results.....	302
APPENDIX F: Vital Signs Listing .....	672
APPENDIX G1: Listing of Protocol Deviations.....	709
APPENDIX G2: Listing of Non-Subject Deviations .....	712
APPENDIX H: Listing of Pregnancies .....	713

## APPENDIX A: Adverse Event Definitions

*(Excerpted from Protocol version 3.0, 30 March 2020)*

### **Definition of Adverse Event (AE)**

AEs means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product.

Any medical condition that is present at the time that the subject is screened will be considered as baseline and not reported as an AE. However, if the severity of any pre-existing medical condition increases, it should be recorded as an AE.

AEs can be further divided into solicited AEs and unsolicited AEs. Solicited AEs are those for which the study team will specifically query the subject whether they occurred. Unsolicited AEs are those events that the subject report occurring without being queried about the specific event.

All AEs will be assessed for severity and relationship to study intervention (see section 8.3.3 of the protocol). Reporting of all AEs, solicited and unsolicited, will occur during the period from study product administration at Day 1 through 28 days after the last vaccination. After Day 57 through the end of study on Day 394, only SAEs, MAAEs, and NOCMCs will be recorded as AEs.

All AEs, solicited and unsolicited, will be captured on the appropriate DCF. Information to be collected for AEs includes event description, date of onset, assessment of severity, relationship to study product and alternate etiology (assessed only by those with the training and authority to make a diagnosis and listed on the Form FDA 1572 as the participating site PI or appropriate sub-investigator), date of resolution, seriousness, and outcome. AEs occurring during the study-collection and reporting period will be documented appropriately regardless of relationship.

AEs will be followed to resolution or stabilization.

**Severity of Adverse Events:** All AEs or SAEs will be assessed for severity, according to the toxicity grading scales in the FDA “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials”.

For AEs not included in the protocol-defined grading system, the following guidelines will be used to describe severity.

- **Mild (Grade 1)**: Events that are usually transient and may require only minimal or no treatment or therapeutic intervention and generally do not interfere with the subject’s usual activities of daily living.
- **Moderate (Grade 2)**: Events that are usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research subject.

## **Appendix A (continued)** **Adverse Events Definitions**

*(Excerpted from Protocol version 3.0, 30 March 2020)*

- **Severe (Grade 3):** Events interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating.

AEs characterized as intermittent require documentation of onset and duration of each episode. The start and stop date of each reported AE will be recorded on the appropriate DCF. Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of intensity.

**Relationship to Study Intervention:** For each reported adverse reaction, the participating site PI or qualified designee must assess the relationship of the event to the study product using the following guidelines:

- **Related** – The AE is known to occur with the study intervention, there is a reasonable possibility that the study intervention caused the AE, or there is a temporal relationship between the study intervention and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study intervention and the AE.
- **Not Related** – There is not a reasonable possibility that the administration of the study intervention caused the event, there is no temporal relationship between the study intervention and event onset, or an alternate etiology has been established.

### **Definition of Serious Adverse Event (SAE)**

An SAE is defined in 21 CFR 312.32 as follows: “An AE or suspected adverse reaction is considered serious if, in the view of either the participating site PI or appropriate sub-investigator or the sponsor, it results in any of the following outcomes:

- Death,
- a life-threatening AE,
- inpatient hospitalization or prolongation of existing hospitalization,
- a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions,
- or a congenital anomaly/birth defect.

Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.



**Appendix A (continued)**  
**Adverse Events Definitions**

*(Excerpted from Protocol version 3.0, 30 March 2020)*

“Life-threatening” refers to an AE that at occurrence represents an immediate risk of death to a subject. An event that may cause death if it occurs in a more severe form is not considered life-threatening. Similarly, a hospital admission for an elective procedure is not considered an SAE.

All SAEs, as with any AE, will be assessed for severity and relationship to study intervention.

All SAEs will be recorded on the appropriate SAE DCF.

All SAEs will be followed through resolution or stabilization by a study clinician, licensed to make medical diagnoses and listed on the Form FDA 1572 as the participating site PI or appropriate sub-investigator.

All SAEs will be reviewed and evaluated by DMID and will be sent to the SMC (for periodic review unless related) and IRB/IEC.

**APPENDIX B:**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	14 (8)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Petechiae
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (0)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	25 (17)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Dyspnoea exertional
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	4 (0)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Flatulence
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	28 (8)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Vascular disorders	Systolic hypertension

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	14 (14)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Erythema
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	1 (3)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	15 (2)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	8 (6)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments: REDACTED									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	6 (2)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	3 (9)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Dermatitis contact
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	2 (2)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin laceration
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	1 (0)	Moderate	Related	REDACTED	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	5 (1)	Mild	Related	REDACTED	WD- Drug withdrawn	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Urticaria
Comments: REDACTED									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (0)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscular weakness
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	0 (8)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 003</b>									
REDACTED	8 (3)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	5 (7)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 001</b>									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	22 (1)	Moderate	Not related	REDACTED	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	20 (3)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Fatigue
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003</b>									
REDACTED	1 (8)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Injection site irritation
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 004</b>									
REDACTED	14 (Ongoing)	Mild	Not Related	REDACTED	Not Applicable	No		Injury, poisoning and procedural complications	Contusion
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 005</b>									
REDACTED	18 (0)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Nervous system disorders	Presyncope
Comments: REDACTED									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 004</b>									
REDACTED	8 (7)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 005</b>									
REDACTED	11 (3)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 006</b>									
REDACTED	25 (Ongoing)	Mild	Not related	REDACTED	Not applicable	No		Injury, poisoning and procedural complications	Contusion
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	13 (14)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Investigations	Heart rate increased
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	4 (3)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	9 (6)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	6 (6)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	14 (27)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Thermal burn
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	1 (1)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Dizziness



**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	1 (13)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	3 (0)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Vascular disorders	Vasodilatation
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	2 (0)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (15)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	0 (7)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 003</b>									
REDACTED	7 (1)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	1 (0)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Nasal congestion
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	20 (4)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Reproductive system and breast disorders	Breast pain
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	14 (Ongoing)	Mild	Not related	REDACTED	Not applicable	No	Recovering /resolving	Cardiac disorders	Bradycardia

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (1)	Moderate	Related	REDACTED	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Abdominal pain
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	2 (1)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Neck pain
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003</b>									
REDACTED	22 (Ongoing)	Mild	Not related	REDACTED	Not applicable	No		Injury, poisoning and procedural complications	Muscle strain
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003</b>									
REDACTED	1 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Diaphragmatic spasm
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 004</b>									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	0 (3)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 005</b>									
REDACTED	1 (0)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Feeling jittery
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 006</b>									
REDACTED	1 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Eye disorders	Eye irritation
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 007</b>									
REDACTED	4 (0)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Abdominal discomfort
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 008</b>									
REDACTED	3 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments: REDACTED									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
<b>Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 009</b>									
REDACTED	4 (11)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Faeces discoloured
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	10 (0)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	27 (0)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (1)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	6 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No	Recovering /resolving	Reproductive system and breast disorders	Vulvovaginal pruritus
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 003</b>									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	8 (12)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 004</b>									
REDACTED	21 (7)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Lip disorder
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	12 (3)	Moderate	Related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site erythema
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	6 (0)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Vascular disorders	Hypertension
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	2 (0)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Arthralgia
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	24 (3)	Mild	Not related	REDACTED	WD- Drug withdrawn	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	10 (1)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site erythema
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (1)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Reproductive system and breast disorders	Vaginal haemorrhage
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	7 (4)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	14 (14)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Cardiac disorders	Bradycardia

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 005</b>									
REDACTED	28 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No		Vascular disorders	Hypotension
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	11 (7)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscle strain
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	7 (Ongoing)	Moderate	Not related	REDACTED	Not applicable	No	Recovering /resolving	Metabolism and nutrition disorders	Hypoglycaemia
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	7 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Abdominal pain upper
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	1 (0)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscle spasms



**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003</b>									
REDACTED	1 (0)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	1 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003</b>									
REDACTED	1 (0)	Severe	Related	REDACTED	Not applicable	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 004</b>									
REDACTED	1 (0)	Severe	Related	REDACTED	Not applicable	No	Recovered /resolved	Nervous system disorders	Syncope
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 005</b>									
REDACTED	1 (Ongoing)	Mild	Not related	REDACTED	Not applicable	No		General disorders and administration site conditions	Vessel puncture site bruise

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 006</b>									
REDACTED	13 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Eye disorders	Scintillating scotoma
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	0 (2)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003</b>									
REDACTED	0 (1)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Hyperhidrosis
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 004</b>									
REDACTED	7 (Ongoing)	Mild	Not related	REDACTED	Not applicable	No		Psychiatric disorders	Insomnia
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 005</b>									
REDACTED	1 (Ongoing)	Mild	Related	REDACTED	Not applicable	No		Psychiatric disorders	Anxiety
Comments: REDACTED									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003</b>									
REDACTED	1 (1)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Malaise
Comments: REDACTED									
<b>Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 004</b>									
REDACTED	2 (0)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Night sweats
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	27 (0)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	5 (1)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Sciatica
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	12 (0)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Exposure via inhalation
Comments: REDACTED									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
<b>Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	1 (1)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	1 (11)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (4)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vaccination site bruising
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	28 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No	Recovering /resolving	Vascular disorders	Diastolic hypertension
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 02, Subject ID: REDACTED, AE Number: 001</b>									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	1 (1)	Moderate	Related	REDACTED	Not Applicable	No	Recovered /Resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 02, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (1)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Psychiatric disorders	Insomnia
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	13 (2)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Nasal congestion
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	21 (1)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	2 (13)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Infections and infestations	Paronychia
Comments: REDACTED									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
<b>Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	9 (Ongoing)	Moderate	Not related	REDACTED	WD- Drug withdrawn	No	Recovering /resolving	Skin and subcutaneous tissue disorders	Rash maculo-papular
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	14 (15)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Vascular disorders	Systolic hypertension
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	8 (5)	Severe	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Hypoglycaemia
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 02, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	1 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Ear and labyrinth disorders	Vertigo
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	4 (9)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Sunburn
Comments: REDACTED									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
<b>Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	2 (1)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Joint swelling
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (0)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	2 (2)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Night sweats
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 003</b>									
REDACTED	4 (0)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Psychiatric disorders	Anxiety
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (3)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Energy increased
Comments: REDACTED									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
<b>Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	1 (12)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									
REDACTED	1 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No		Injury, poisoning and procedural complications	Skin abrasion
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (0)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Pruritus
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (10)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									



**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	2 (10)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments: REDACTED									
<b>Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 003</b>									
REDACTED	3 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No		Injury, poisoning and procedural complications	Arthropod bite
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (10)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Dermatitis
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	0 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No		General disorders and administration site conditions	Injection site bruising
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002</b>									

**Appendix B (continued)**  
**Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	0 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No		General disorders and administration site conditions	Vessel puncture site bruise
Comments: REDACTED									
<b>Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001</b>									
REDACTED	3 (1)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments: REDACTED									

**APPENDIX C1:  
Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.3	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.5	Moderate	Moderate	Moderate	Mild	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.3 (Mild)	Moderate	Moderate	Moderate	Mild	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.3 (Mild)	Mild	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.4	None	None	None	None	None	Moderate
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	Mild	None	Moderate	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.9	None	None	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.6 (Moderate)	Mild	Moderate	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.5	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.1 (Mild)	Moderate	Moderate	Moderate	None	Moderate	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.4	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.3	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.6	None	Mild	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.2	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.6	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	None	Moderate	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	Moderate	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	None	None	None	Mild	Moderate	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	Mild	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.3	None	Moderate	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.3	None	Mild	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	Mild	Mild	Mild	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	Mild	None	Mild	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	Mild	None	Mild	Moderate	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	Mild	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.4	None	None	None	Mild	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 9	MA	N/A				Mild		
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.3	None	None	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.7	Mild	Moderate	Moderate	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	Mild	Mild	Mild	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.5	None	Moderate	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.5	None	Mild	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	Mild
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.4	None	Mild	None	None	None	Mild
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	Mild	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	Mild	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.3 (Mild)	Moderate	Moderate	Moderate	Moderate	Mild	Moderate
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	Moderate	Moderate	Moderate	Mild	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	Mild	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.4	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.1	None	None	Mild	None	Mild	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	Mild	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.8	Mild	Moderate	Moderate	Mild	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.2	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	37.1	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	39.2 (Severe)	Moderate	Moderate	Moderate	Moderate	Moderate	Mild
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	Moderate	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.9	None	None	None	None	Mild	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	Mild	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.3	None	Mild	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37.4	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.3	Moderate	Mild	Moderate	Moderate	Moderate	Moderate
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.4	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.9	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	38.4 (Mild)	Mild	Mild	Mild	None	Mild	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.1	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	Mild	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.9	None	Moderate	Mild	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None

Report Date: 02JUN2020  
 Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.9	None	None	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.4	None	Moderate	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.6	None	None	None	None	None	None

Report Date: 02JUN2020  
 Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Report Date: 02JUN2020  
 Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	Mild	Moderate	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	Mild	Mild	Mild	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Report Date: 02JUN2020  
 Data Cutoff Date: 25MAY2020



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	Mild	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.8	Mild	Moderate	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	Mild	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.7	Moderate	Moderate	Moderate	Moderate	Mild	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.2	Mild	Mild	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	Mild	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 12	MA	N/A			Mild			
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37	Mild	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	Mild	Mild	None	None	None	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	35.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.3	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	Moderate	None	None	None	Moderate	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.1	Moderate	Moderate	Mild	Mild	Moderate	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	Mild	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.5	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.4	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	Mild	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.9	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	Mild	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	Mild	None	Moderate	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	Mild	None	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	Mild	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	Mild	Mild	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.4	None	None	None	Moderate	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 10	MA	N/A				Mild		
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	36.4	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.5	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	36.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	35.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.4	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.4	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	Mild	Mild	Mild	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.4	None	None	Mild	Mild	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.5	None	None	None	None	None	None

Report Date: 02JUN2020  
 Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.4	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.8	Moderate	Moderate	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.8	None	None	Mild	None	Mild	Mild
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.2	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.2	None	Mild	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.7	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	35.7	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	35.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	35.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	35.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	Mild	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.5	None	Moderate	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.7	Moderate	Mild	Moderate	None	Mild	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.2	None	Mild	Mild	None	Mild	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	Moderate	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.4 (Mild)	Moderate	None	Moderate	None	Mild	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	Mild	None	Mild	None	None	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37	None	Mild	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.2	Mild	Moderate	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.2	Mild	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.1	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	Mild	Mild	None	None	Moderate	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	Mild	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37	None	None	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.4	Mild	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.1	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.2	None	Mild	None	None	Moderate	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	Mild	Mild	Mild	Moderate	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.5	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.5	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	Moderate	None	None	Mild	Moderate
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.3 (Mild)	Mild	None	Mild	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	N/A	Not Done	Not Done	Not Done	Not Done	Not Done	Not Done
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	None	Moderate	Moderate	Moderate	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
 Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
 Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.4 (Mild)	Moderate	None	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38 (Mild)	Mild	None	None	Mild	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	Mild	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.5	None	Mild	Mild	None	Moderate	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	None	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.3	Severe	Mild	Mild	None	Mild	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	39.6 (Severe)	Severe	Severe	Moderate	Mild	Severe	Moderate
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	Mild	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.4	Mild	Mild	None	None	Moderate	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.8	None	Mild	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.8 (Moderate)	Severe	Severe	Moderate	Moderate	Moderate	Mild
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	Mild	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	Mild	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.6 (Moderate)	Severe	None	Severe	None	None	Severe
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.8	None	Mild	Mild	None	Mild	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	Mild	Mild	None	Moderate	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	Mild	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.1	None	Moderate	Mild	None	Moderate	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	Mild	Moderate	Moderate	Moderate	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	Mild	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	N/A	Not Done	Not Done	Not Done	Not Done	Not Done	Not Done
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.3	Mild	Moderate	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.7	None	Mild	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.2 (Mild)	Moderate	Moderate	Mild	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	Moderate	Moderate	Mild	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.1	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.6	None	Mild	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	37.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.8	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.2	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	Mild	Mild	Mild	Mild	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.8	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	37.2	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	37.2	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	37.3	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.2	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.9	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	37.2	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 14	MA	N/A			Mild			
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.5	None	Mild	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	37.1	None	Mild	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.8	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None



**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	Mild	Mild	None	None	None

**Appendix C1 (continued)**  
**Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	Mild	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	37.1	None	None	None	None	None	None

\*MA = Data reported by subject on the Memory Aid and reviewed by clinic staff and reported in Solicited Events eCRF.  
Clinic = Data collected by clinic staff during physical exam or symptom assessment (treatment administration record, in-clinic assessment, etc.)  
See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**APPENDIX C2:  
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Report Date: 02JUN2020  
 Data Cutoff Date: 25MAY2020

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	Mild	0	1
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	2
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	2
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	Moderate	0	75 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	Moderate	0	78 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	Mild	0	36 (Mild)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	Mild	0	26 (Mild)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	Moderate	0	65 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	Moderate	0	76 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	23
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	Mild	0	35 (Mild)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	20
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	None	0	15
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	Mild	None	1	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	Mild	None	1	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	Mild	None	3	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	Mild	None	3	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	Mild	None	3	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	Mild	None	2	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	Mild	None	2	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	Mild	None	2	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 10	MA	.	Mild	.	2	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	Mild	None	1	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	1

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	10
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	Mild	None	None	0	8
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	Mild	0	3
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	Mild	0	2
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	3	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	Mild	None	2	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	Mild	None	2	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	Mild	None	3	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	Mild	None	2	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	Mild	None	65 (Moderate)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	None	65 (Moderate)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	Mild	None	40 (Mild)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	Mild	None	40 (Mild)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	None	50 (Moderate)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	Mild	None	25 (Mild)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	Mild	0	50 (Moderate)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	Mild	0	15
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	20
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	5



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	Mild	0	1
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	Mild	Mild	Mild	2	3
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Moderate	None	Mild	0	50 (Moderate)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	3
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	Mild	0	2
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	Mild	Mild	5	30 (Mild)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	Mild	Mild	60 (Moderate)	45 (Mild)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	Mild	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	Mild	None	35 (Mild)	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	Mild	Mild	40 (Mild)	40 (Mild)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 12	MA	.	Mild	Mild	110 (Severe)	40 (Mild)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	Mild	0	50 (Moderate)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	Mild	Mild	80 (Moderate)	80 (Moderate)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	Mild	115 (Severe)	90 (Moderate)

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	Mild	Mild	80 (Moderate)	80 (Moderate)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	Mild	Mild	None	60 (Moderate)	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	Mild	None	60 (Moderate)	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	Not Done	Not Done	Not Done	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	Mild	None	20	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	Mild	None	20	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	Mild	0	7
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	Mild	0	30 (Mild)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	Mild	0	20
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	Mild	0	30 (Mild)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	Mild	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	Mild	0	1
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	Mild	0	1
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	Mild	None	50 (Moderate)	50 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 12	MA	.	Mild	.	105 (Severe)	105 (Severe)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	Mild	Mild	10	60 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	Mild	Mild	75 (Moderate)	60 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	Mild	105 (Severe)	25 (Mild)

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	Mild	None	60 (Moderate)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	Not Done	Not Done	Not Done	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	Mild	None	2	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	Mild	None	20	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	Mild	None	20	20
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0



**Appendix C2 (continued)**  
**Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0

\*MA = Data reported by subject on the Memory Aid and reviewed by clinic staff and reported in Solicited Events eCRF.  
Clinic = Data collected by clinic staff during physical exam or symptom assessment (treatment administration record, in-clinic assessment, etc.)  
See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**APPENDIX D:**  
**Attribution for Systemic Solicited Events that Contribute to Halting Criteria**

<b>Subject ID</b>	<b>Vaccination Group</b>	<b>Systemic Reaction</b>	<b>Dose Number</b>	<b>Post-Dose Day</b>	<b>Severity</b>	<b>Attributed to Alternate Etiology?</b>
REDACTED	25 mcg mRNA-1273 (56-70 years)	Fever	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Fatigue	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	1	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Headache	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Fever	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Fatigue	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Myalgia	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Nausea	02	2	SEVERE	No

**APPENDIX E:  
Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Hemoglobin (g/dL)	14.0 (Mild)	NOT RELATED	Grade 1, due to phlebotomy procedure	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	PT (seconds)	11.8 (Mild)	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-14	PT (seconds)	10.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	PTT (seconds)	34 (Mild)	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Platelets (10 <sup>3</sup> /uL)	190	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	182	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	204	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	197	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Platelets (10 <sup>3</sup> /uL)	212	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	WBC (10 <sup>3</sup> /uL)	3.7	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	WBC (10 <sup>3</sup> /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	WBC (10 <sup>3</sup> /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	85	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	86	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Grade 1 Due to study procedures phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PT (seconds)	10.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PTT (seconds)	32	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Platelets (10 <sup>3</sup> /uL)	332	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	334	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Platelets (10 <sup>3</sup> /uL)	358	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Platelets (10 <sup>3</sup> /uL)	343	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	366	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	WBC (10 <sup>3</sup> /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	WBC (10 <sup>3</sup> /uL)	6.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	WBC (10 <sup>3</sup> /uL)	6.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	13.7 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Grade 1 Due to study procedures phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	PTT (seconds)	28	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Platelets (10 <sup>3</sup> /uL)	201	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	200	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	217	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Platelets (10 <sup>3</sup> /uL)	206	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	238	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	WBC (10 <sup>3</sup> /uL)	7.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.9	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	WBC (10 <sup>3</sup> /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Hemoglobin (g/dL)	15.6 (Mild)	NOT RELATED	Due to phlebotomy (study procedure)	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Platelets (10 <sup>3</sup> /uL)	163	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	185	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Platelets (10 <sup>3</sup> /uL)	195	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Platelets (10 <sup>3</sup> /uL)	170	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Platelets (10 <sup>3</sup> /uL)	162	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	1.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-2	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	1.4 (Mild)	NOT RELATED	Grade 1 Similar to baseline bilirubin	NC- DOSE NOT CHANGED	No

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	57	55	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	WBC (10 <sup>3</sup> /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	WBC (10 <sup>3</sup> /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	WBC (10 <sup>3</sup> /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	WBC (10 <sup>3</sup> /uL)	3.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PT (seconds)	11.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Platelets (10 <sup>3</sup> /uL)	215	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	206	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	221	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	219	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Platelets (10 <sup>3</sup> /uL)	237	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	WBC (10 <sup>3</sup> /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	WBC (10 <sup>3</sup> /uL)	5.1	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	PT (seconds)	11.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	PTT (seconds)	27	N/A	N/A	N/A	N/A

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Platelets (10 <sup>3</sup> /uL)	222	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	226	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	252	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	227	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	231	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Serum Lipase (U/L)	53.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	53.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	78.0 (Mild)	RELATED	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	70.0 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	57	56	Serum Lipase (U/L)	77.0 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	WBC (10 <sup>3</sup> /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	3.2 (Mild)	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	2.8 (Mild)	NOT RELATED	Grade I - similar to Grade I that was present prior to receipt of vaccine	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	3.0 (Mild)	NOT RELATED	Grade 1 Similar to her baseline	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	57	56	WBC (10 <sup>3</sup> /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Creatinine (mg/dL)	1.08	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.7	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	15.5 (Mild)	NOT RELATED	Due to study - phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.3 (Mild)	NOT RELATED	Grade 1 Due to study procedures phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Hemoglobin (g/dL)	15.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PT (seconds)	10.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Platelets (10 <sup>3</sup> /uL)	175	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	168	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	174	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	170	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Platelets (10 <sup>3</sup> /uL)	189	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	WBC (10 <sup>3</sup> /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	WBC (10 <sup>3</sup> /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Creatinine (mg/dL)	0.76	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	Grade I due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	Grade I Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	PT (seconds)	9.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	PTT (seconds)	29	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Platelets (10 <sup>3</sup> /uL)	291	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	275	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Platelets (10 <sup>3</sup> /uL)	282	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Platelets (10 <sup>3</sup> /uL)	281	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	318	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Serum Lipase (U/L)	64.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-19	Serum Lipase (U/L)	55.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	47.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	55.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	59.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	WBC (10 <sup>3</sup> /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	WBC (10 <sup>3</sup> /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	WBC (10 <sup>3</sup> /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alanine Aminotransferase (U/L)	33	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	72	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.12	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Creatinine (mg/dL)	1.16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Hemoglobin (g/dL)	14.7 (Moderate)	RELATED	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Platelets (10 <sup>3</sup> /uL)	267	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	266	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Platelets (10 <sup>3</sup> /uL)	266	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	241	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	253	N/A	N/A	N/A	N/A

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Serum Lipase (U/L)	112.0 (Moderate)	RELATED	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	WBC (10 <sup>3</sup> /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	WBC (10 <sup>3</sup> /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	6.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Creatinine (mg/dL)	1.05	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Hemoglobin (g/dL)	16.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	14.0 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	PT (seconds)	11.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-4	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	PTT (seconds)	36 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-4	PTT (seconds)	34 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Platelets (10 <sup>3</sup> /uL)	304	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	267	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Platelets (10 <sup>3</sup> /uL)	283	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Platelets (10 <sup>3</sup> /uL)	277	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Serum Lipase (U/L)	61.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	56.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	56.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	WBC (10 <sup>3</sup> /uL)	8.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	WBC (10 <sup>3</sup> /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	WBC (10 <sup>3</sup> /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	study procedures -phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PT (seconds)	11.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	213	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	228	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	217	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Platelets (10 <sup>3</sup> /uL)	203	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	WBC (10 <sup>3</sup> /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	72	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	72	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	199	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	181	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	196	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	204	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	6.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	6.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	209	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	192	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	189	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	185	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	9.0	N/A	N/A	N/A	N/A

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	6.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	105	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	103	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	104	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	102	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	320	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	332	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	337	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	352	N/A	N/A	N/A	N/A

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	8.6	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	8.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	9.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	8.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Creatinine (mg/dL)	0.89	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Hemoglobin (g/dL)	13.1 (Moderate)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	206	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	221	N/A	N/A	N/A	N/A

Report Date: 02JUN2020  
 Data Cutoff Date: 25MAY2020

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	217	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Platelets (10 <sup>3</sup> /uL)	221	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	6.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	WBC (10 <sup>3</sup> /uL)	6.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	216	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	199	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Platelets (10 <sup>3</sup> /uL)	216	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Platelets (10 <sup>3</sup> /uL)	202	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	57.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	WBC (10 <sup>3</sup> /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	WBC (10 <sup>3</sup> /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	study procedures - phlebotomy	NC- DOSE NOT CHANGED	No

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	Grade 1, due to phlebotomy	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	31	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	371	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	355	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	370	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	352	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	46.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (U/L)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	7.3	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	7.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	79	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	79	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Creatinine (mg/dL)	1.08	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	267	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	267	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	256	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	250	N/A	N/A	N/A	N/A

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	56.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	65.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	7.2	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	study procedures -phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Hemoglobin (g/dL)	12.2 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Platelets (10 <sup>3</sup> /uL)	361	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	395	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	388	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Platelets (10 <sup>3</sup> /uL)	350	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	37.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	WBC (10 <sup>3</sup> /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	6.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	WBC (10 <sup>3</sup> /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.61	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Platelets (10 <sup>3</sup> /uL)	350	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	352	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Platelets (10 <sup>3</sup> /uL)	346	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Platelets (10 <sup>3</sup> /uL)	358	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	42.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	45.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Serum Lipase (U/L)	45.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	WBC (10 <sup>3</sup> /uL)	6.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	WBC (10 <sup>3</sup> /uL)	4.4	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	52 (Mild)	NOT RELATED	Related to Alcohol	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	37	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	86	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	90	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	13.4 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PT (seconds)	9.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PTT (seconds)	33	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Platelets (10 <sup>3</sup> /uL)	367	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	321	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	379	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	367	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	345	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	WBC (10 <sup>3</sup> /uL)	6.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	88 (Mild)	NOT RELATED	subject confirmed alcohol use	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	91	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Creatinine (mg/dL)	1.18	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Creatinine (mg/dL)	1.26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	13.1 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Platelets (10 <sup>3</sup> /uL)	359	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	321	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	328	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	302	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Platelets (10 <sup>3</sup> /uL)	348	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	WBC (10 <sup>3</sup> /uL)	8.2	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	7.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	7.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	6.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	WBC (10 <sup>3</sup> /uL)	6.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.76	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Creatinine (mg/dL)	0.72	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Platelets (10 <sup>3</sup> /uL)	265	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	245	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	260	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Platelets (10 <sup>3</sup> /uL)	235	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	267	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	WBC (10 <sup>3</sup> /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	WBC (10 <sup>3</sup> /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	Normal variation	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	normal lab variation	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	11.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	247	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	222	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	217	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	211	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Platelets (10 <sup>3</sup> /uL)	249	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	WBC (10 <sup>3</sup> /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Creatinine (mg/dL)	0.72	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.0 (Mild)	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	PT (seconds)	10.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Platelets (10 <sup>3</sup> /uL)	354	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	373	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Platelets (10 <sup>3</sup> /uL)	420	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	415	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Platelets (10 <sup>3</sup> /uL)	407	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	WBC (10 <sup>3</sup> /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	WBC (10 <sup>3</sup> /uL)	6.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	5.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	study procedures - phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	related to study procedure	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Hemoglobin (g/dL)	13.6 (Mild)	.	.	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	PT (seconds)	10.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Platelets (10 <sup>3</sup> /uL)	211	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	187	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	186	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	195	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Platelets (10 <sup>3</sup> /uL)	199	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	WBC (10 <sup>3</sup> /uL)	8.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.2	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	7.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	WBC (10 <sup>3</sup> /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Alanine Aminotransferase (U/L)	6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	study procedures - phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	12.2 (Moderate)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Platelets (10 <sup>3</sup> /uL)	270	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	278	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	285	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Platelets (10 <sup>3</sup> /uL)	273	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	238	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	WBC (10 <sup>3</sup> /uL)	8.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	7.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	8.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	WBC (10 <sup>3</sup> /uL)	7.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	12.7 (Mild)	NOT RELATED	related to study blood draws	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	normal variation	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	12.2 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	PT (seconds)	9.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Platelets (10 <sup>3</sup> /uL)	332	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	324	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Platelets (10 <sup>3</sup> /uL)	343	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	308	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	320	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	WBC (10 <sup>3</sup> /uL)	7.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	8.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	study procedure (phlebotomy)	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Platelets (10 <sup>3</sup> /uL)	173	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	180	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	159	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	180	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Platelets (10 <sup>3</sup> /uL)	188	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Serum Lipase (U/L)	60.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	67.0 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	WBC (10 <sup>3</sup> /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	WBC (10 <sup>3</sup> /uL)	4.1	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Alkaline Phosphatase (U/L)	87	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	83	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	83	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	15.0 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.4 (Mild)	.	.	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Platelets (10 <sup>3</sup> /uL)	232	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	226	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	215	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	217	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	WBC (10 <sup>3</sup> /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	91	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	80	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	86	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.10	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	Normal variation or phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	279	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	278	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	269	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	278	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	7.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	8.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	7.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.12	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.06	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.8 (Moderate)	NOT RELATED	Large volume phlebotomy at V01	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.1 (Severe)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	280	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	312	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	273	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	271	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	6.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	6.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.56	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Creatinine (mg/dL)	0.56	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.8 (Mild)	NOT RELATED	Large volume phlebotomy at V01	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Hemoglobin (g/dL)	12.3 (Mild)	.	.	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	310	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	320	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	316	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Platelets (10 <sup>3</sup> /uL)	287	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	8.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	7.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	WBC (10 <sup>3</sup> /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	13.6 (Moderate)	NOT RELATED	Large volume phlebotomy at V01	NC- DOSE NOT CHANGED	No

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	167	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	167	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	159	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	163	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	5.7	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Alkaline Phosphatase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	37	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Platelets (10 <sup>3</sup> /uL)	287	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	284	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	287	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	283	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	WBC (10 <sup>3</sup> /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	54 (Mild)	NOT RELATED	alcohol consumption	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Platelets (10 <sup>3</sup> /uL)	219	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	221	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	240	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Platelets (10 <sup>3</sup> /uL)	222	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	WBC (10 <sup>3</sup> /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	WBC (10 <sup>3</sup> /uL)	4.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	53 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	43	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Alanine Aminotransferase (U/L)	46	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Hemoglobin (g/dL)	16.4	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Hemoglobin (g/dL)	16.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PT (seconds)	10.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Platelets (10 <sup>3</sup> /uL)	264	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	186	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	225	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Platelets (10 <sup>3</sup> /uL)	183	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Platelets (10 <sup>3</sup> /uL)	193	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	WBC (10 <sup>3</sup> /uL)	7.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	6.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	WBC (10 <sup>3</sup> /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	WBC (10 <sup>3</sup> /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	PT (seconds)	11.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Platelets (10 <sup>3</sup> /uL)	269	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	270	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	282	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Platelets (10 <sup>3</sup> /uL)	290	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Platelets (10 <sup>3</sup> /uL)	287	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Serum Lipase (U/L)	60.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	46.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	WBC (10 <sup>3</sup> /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	WBC (10 <sup>3</sup> /uL)	3.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	WBC (10 <sup>3</sup> /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Alkaline Phosphatase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	34	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	32	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Alkaline Phosphatase (U/L)	33	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Hemoglobin (g/dL)	10.6 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Hemoglobin (g/dL)	11.2 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	PT (seconds)	11.5 (Mild)	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Platelets (10 <sup>3</sup> /uL)	235	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	224	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	231	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Platelets (10 <sup>3</sup> /uL)	231	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Platelets (10 <sup>3</sup> /uL)	274	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	WBC (10 <sup>3</sup> /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.4	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	WBC (10 <sup>3</sup> /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	WBC (10 <sup>3</sup> /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Aspartate Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	11.6 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	PT (seconds)	9.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	PTT (seconds)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Platelets (10 <sup>3</sup> /uL)	278	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	317	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	319	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Platelets (10 <sup>3</sup> /uL)	295	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Platelets (10 <sup>3</sup> /uL)	295	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	WBC (10 <sup>3</sup> /uL)	8.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	3.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	WBC (10 <sup>3</sup> /uL)	3.5 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	WBC (10 <sup>3</sup> /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.61	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	PT (seconds)	10.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Platelets (10 <sup>3</sup> /uL)	248	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	245	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Platelets (10 <sup>3</sup> /uL)	251	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	235	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	272	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	WBC (10 <sup>3</sup> /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	WBC (10 <sup>3</sup> /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	3.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	36	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	32	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.76	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	11.1 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	10.5 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	10.3 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	10.6 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	PT (seconds)	9.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Platelets (10 <sup>3</sup> /uL)	307	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	254	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Platelets (10 <sup>3</sup> /uL)	251	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	243	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	297	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	47.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	51.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	46.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	WBC (10 <sup>3</sup> /uL)	4.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	3.4 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	WBC (10 <sup>3</sup> /uL)	3.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	3.3 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	3.8	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.06	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	12.9 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	PTT (seconds)	31	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Platelets (10 <sup>3</sup> /uL)	245	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	240	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	217	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	272	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	272	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	WBC (10 <sup>3</sup> /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	3.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	3.2 (Mild)	RELATED	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	4.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	66 (Mild)	NOT RELATED	increased alcohol night before	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.3 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	15.5 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	PTT (seconds)	32	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Platelets (10 <sup>3</sup> /uL)	221	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	219	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	219	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	232	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	227	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	8.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	WBC (10 <sup>3</sup> /uL)	8.3	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	8.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	8.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	8.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	7.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	11.5 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	57	58	Hemoglobin (g/dL)	11.6 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	PT (seconds)	10.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Platelets (10 <sup>3</sup> /uL)	302	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	290	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Platelets (10 <sup>3</sup> /uL)	247	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	234	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	260	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	61.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	WBC (10 <sup>3</sup> /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	WBC (10 <sup>3</sup> /uL)	3.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	PT (seconds)	9.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Platelets (10 <sup>3</sup> /uL)	240	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	269	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Platelets (10 <sup>3</sup> /uL)	289	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	246	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	280	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	WBC (10 <sup>3</sup> /uL)	7.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	7.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	WBC (10 <sup>3</sup> /uL)	7.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	7.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	6.9	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	61	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	PT (seconds)	11.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	PTT (seconds)	29	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Platelets (10 <sup>3</sup> /uL)	280	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	221	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	253	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	231	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	255	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	WBC (10 <sup>3</sup> /uL)	4.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	2.9 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	3.2 (Mild)	RELATED	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	2.8 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	2.7 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.89	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Platelets (10 <sup>3</sup> /uL)	313	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	264	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	227	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	273	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	274	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	WBC (10 <sup>3</sup> /uL)	5.4	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Alanine Aminotransferase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-7	Alanine Aminotransferase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-7	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	61	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-7	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-7	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Hemoglobin (g/dL)	16.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Platelets (10 <sup>3</sup> /uL)	298	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	285	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	311	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	309	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Platelets (10 <sup>3</sup> /uL)	310	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	16.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	WBC (10 <sup>3</sup> /uL)	6.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	5.7	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	WBC (10 <sup>3</sup> /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	45 (Mild)	NOT RELATED	Alcohol intake	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Creatinine (mg/dL)	0.71	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Hemoglobin (g/dL)	15.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PT (seconds)	10.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Platelets (10 <sup>3</sup> /uL)	286	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	248	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	251	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	249	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	257	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	WBC (10 <sup>3</sup> /uL)	6.3	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	3.5 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Creatinine (mg/dL)	0.52	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.57	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.59	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.53	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.7 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	PT (seconds)	10.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Platelets (10 <sup>3</sup> /uL)	241	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	249	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	293	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	224	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	257	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	WBC (10 <sup>3</sup> /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	6.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	53 (Mild)	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Hemoglobin (g/dL)	16.6	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.7 (Moderate)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	16.1 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Hemoglobin (g/dL)	16.2 (Mild)	.	.	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	PT (seconds)	10.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Platelets (10 <sup>3</sup> /uL)	251	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	223	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	252	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Platelets (10 <sup>3</sup> /uL)	195	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	269	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	WBC (10 <sup>3</sup> /uL)	4.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	WBC (10 <sup>3</sup> /uL)	3.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	3.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	13.4 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	13.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PT (seconds)	10.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Platelets (10 <sup>3</sup> /uL)	200	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	172	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	167	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	148	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	163	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	WBC (10 <sup>3</sup> /uL)	7.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.6	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.9 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	PT (seconds)	10.8	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Platelets (10 <sup>3</sup> /uL)	327	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	312	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	324	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	302	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	335	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	1.6 (Mild)	NOT RELATED	suspected gilberts	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	2.1 (Moderate)	NOT RELATED	suspected Gilberts	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	1.8 (Mild)	NOT RELATED	Other	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	WBC (10 <sup>3</sup> /uL)	8.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.9	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	6.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	6.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	6.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Alkaline Phosphatase (U/L)	31	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.63	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.63	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	11.6 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Platelets (10 <sup>3</sup> /uL)	234	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	209	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	200	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Platelets (10 <sup>3</sup> /uL)	227	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	219	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	WBC (10 <sup>3</sup> /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	WBC (10 <sup>3</sup> /uL)	4.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	16.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Hemoglobin (g/dL)	14.8 (Mild)	.	.	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	PTT (seconds)	25	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Platelets (10 <sup>3</sup> /uL)	241	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	266	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	265	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	287	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Platelets (10 <sup>3</sup> /uL)	284	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	58.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Serum Lipase (U/L)	61.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	1.5 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	WBC (10 <sup>3</sup> /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	WBC (10 <sup>3</sup> /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Creatinine (mg/dL)	0.56	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.57	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Hemoglobin (g/dL)	13.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	PT (seconds)	9.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Platelets (10 <sup>3</sup> /uL)	317	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	278	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	281	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	301	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Total Bilirubin (mg/dL)	0.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	WBC (10 <sup>3</sup> /uL)	7.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	7.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	6.1	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Alkaline Phosphatase (U/L)	105	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	122	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	105	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	106	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	93	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Hemoglobin (g/dL)	15.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	15.7 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	16.2 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Hemoglobin (g/dL)	15.7 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	PT (seconds)	10.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	PTT (seconds)	28	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Platelets (10 <sup>3</sup> /uL)	199	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	207	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	190	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Platelets (10 <sup>3</sup> /uL)	174	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Platelets (10 <sup>3</sup> /uL)	190	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	WBC (10 <sup>3</sup> /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	5.9	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	WBC (10 <sup>3</sup> /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	WBC (10 <sup>3</sup> /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	40	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	36	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	40	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Platelets (10 <sup>3</sup> /uL)	242	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	245	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	248	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	216	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	261	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	WBC (10 <sup>3</sup> /uL)	3.9	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	3.4 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Platelets (10 <sup>3</sup> /uL)	204	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	193	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	210	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	204	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	245	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	WBC (10 <sup>3</sup> /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	7.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	6.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Hemoglobin (g/dL)	13.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	11.4 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	PT (seconds)	10.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Platelets (10 <sup>3</sup> /uL)	298	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	243	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	247	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	210	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	255	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Serum Lipase (U/L)	9.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	WBC (10 <sup>3</sup> /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	4.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	3.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.72	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	PTT (seconds)	26	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Platelets (10 <sup>3</sup> /uL)	189	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	202	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	193	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 <sup>3</sup> /uL)	216	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 <sup>3</sup> /uL)	221	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	9.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	WBC (10 <sup>3</sup> /uL)	7.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	6.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 <sup>3</sup> /uL)	5.8	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 <sup>3</sup> /uL)	6.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Creatinine (mg/dL)	1.11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.5 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	PT (seconds)	10.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	PTT (seconds)	28	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Platelets (10 <sup>3</sup> /uL)	185	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	200	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	210	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	51.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	45.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	WBC (10 <sup>3</sup> /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	6.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	61	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Creatinine (mg/dL)	0.76	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	PT (seconds)	9.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Platelets (10 <sup>3</sup> /uL)	260	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	250	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	267	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Serum Lipase (U/L)	51.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	52.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	47.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	WBC (10 <sup>3</sup> /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	3.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	PTT (seconds)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Platelets (10 <sup>3</sup> /uL)	203	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	211	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	230	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	67.0 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	WBC (10 <sup>3</sup> /uL)	4.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	PT (seconds)	9.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Platelets (10 <sup>3</sup> /uL)	276	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	273	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	282	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	WBC (10 <sup>3</sup> /uL)	7.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	6.8	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Alkaline Phosphatase (U/L)	95	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	87	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	90	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	PT (seconds)	10.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Platelets (10 <sup>3</sup> /uL)	207	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	213	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	228	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Serum Lipase (U/L)	55.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	52.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	WBC (10 <sup>3</sup> /uL)	6.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	7.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	13.1 (Mild)	.	.	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	PT (seconds)	9.9	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Platelets (10 <sup>3</sup> /uL)	442	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Platelets (10 <sup>3</sup> /uL)	389	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	362	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	363	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	WBC (10 <sup>3</sup> /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Alanine Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	33	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Alkaline Phosphatase (U/L)	92	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	83	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	13.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	PTT (seconds)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Platelets (10 <sup>3</sup> /uL)	151	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	153	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	188	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	WBC (10 <sup>3</sup> /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	3.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	PT (seconds)	11.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	PTT (seconds)	31	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Platelets (10 <sup>3</sup> /uL)	201	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	165	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	176	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Serum Lipase (U/L)	37.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	WBC (10 <sup>3</sup> /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	4.9	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Hemoglobin (g/dL)	11.9 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	PT (seconds)	10.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	PTT (seconds)	31	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Platelets (10 <sup>3</sup> /uL)	219	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	191	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	200	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	67.0 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	WBC (10 <sup>3</sup> /uL)	5.1	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	3.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	3.3 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	40	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Hemoglobin (g/dL)	13.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	PT (seconds)	10.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	PTT (seconds)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Platelets (10 <sup>3</sup> /uL)	366	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	333	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	354	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	WBC (10 <sup>3</sup> /uL)	6.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	6.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.0 (Mild)	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.0 (Mild)	.	.	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Platelets (10 <sup>3</sup> /uL)	204	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	189	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	213	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	WBC (10 <sup>3</sup> /uL)	3.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	WBC (10 <sup>3</sup> /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	3.1 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	3.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Creatinine (mg/dL)	1.10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.11	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	13.0 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	PT (seconds)	9.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Platelets (10 <sup>3</sup> /uL)	204	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	196	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	208	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	WBC (10 <sup>3</sup> /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	6.2	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	12.7 (Mild)	.	.	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	PT (seconds)	9.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	PTT (seconds)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Platelets (10 <sup>3</sup> /uL)	171	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	187	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Platelets (10 <sup>3</sup> /uL)	183	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	WBC (10 <sup>3</sup> /uL)	4.2	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	WBC (10 <sup>3</sup> /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	PT (seconds)	9.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Platelets (10 <sup>3</sup> /uL)	356	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	369	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	357	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	WBC (10 <sup>3</sup> /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	6.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	7.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	13.7 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Platelets (10 <sup>3</sup> /uL)	195	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	186	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	194	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	WBC (10 <sup>3</sup> /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	11.0 (Mild)	.	.	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Platelets (10 <sup>3</sup> /uL)	242	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	257	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	234	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	WBC (10 <sup>3</sup> /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	6.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Creatinine (mg/dL)	0.71	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Hemoglobin (g/dL)	12.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	PT (seconds)	9.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Platelets (10 <sup>3</sup> /uL)	281	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	318	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	303	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.4 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	WBC (10 <sup>3</sup> /uL)	4.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.5	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	4.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Creatinine (mg/dL)	1.05	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	PT (seconds)	10.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	PTT (seconds)	28	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Platelets (10 <sup>3</sup> /uL)	211	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	213	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	213	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A



**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	WBC (10 <sup>3</sup> /uL)	6.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Aspartate Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	PT (seconds)	9.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Platelets (10 <sup>3</sup> /uL)	144	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 <sup>3</sup> /uL)	104 (Moderate)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Platelets (10 <sup>3</sup> /uL)	125 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

**Appendix E (continued)**  
**Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	WBC (10 <sup>3</sup> /uL)	6.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 <sup>3</sup> /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	WBC (10 <sup>3</sup> /uL)	6.5	N/A	N/A	N/A	N/A

**APPENDIX F:  
Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-21	37.2	121	85	80	79.9	184.5
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.6	114	66	81	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.4	108	73	76	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.2	120	82	82	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.3	123	76	82	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	36	36.1	114	77	71	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	37.3	115	80	64	84.4	175.5
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	110	76	64	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	7	36.4	130	82	79	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	14	37.1	130	82	102 (Mild)	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	28	36.4	128	80	73	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	36.6	119	82	75	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	42	36.3	121	79	80	.	.

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	55	37.1	126	83	63	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	37.1	137	98 (Moderate)	78	68.8	169.4
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.4	138	90	73	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	37.2	138	80	78	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	15	37.1	137	90	67	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	28	36.9	133	87	92	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	37.2	136	89	82	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	42	37.1	133	84	78	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	56	37.1	129	84	86	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.8	130	83	63	93	181.7
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	37	128	81	76	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	7	36.8	117	75	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	13	37.2	117	81	73	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	28	36.4	134	89	68	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	34	36.4	109	71	62	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	40	36.9	100	66	78	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	55	36.3	111	75	76	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.7	106	68	51 (Mild)	73.5	172
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.7	129	74	55	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	36.9	122	72	85	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	15	37.1	120	74	55	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	37.1	118	78	58	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	36	36.8	117	69	82	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	36.6	108	76	53 (Mild)	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	55	36.2	113	70	57	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	37.3	116	77	53 (Mild)	69.7	160.7
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	114	78	53 (Mild)	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	37.1	101	67	56	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	13	37.1	109	67	91	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	37.3	106	76	83	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	37.6	107	66	80	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	42	36.9	110	74	96	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	56	36.9	108	74	66	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.9	137	81	63	76.1	170
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	111	71	63	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	36.8	105	65	59	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	15	36.7	111	73	63	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.6	118	69	73	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	36	37	119	66	64	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	37.1	123	77	74	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	57	36.3	114	69	76	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-20	37.3	115	73	76	55.7	157.5



**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	37.2	120	78	66	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	7	37.3	107	74	74	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	16	37.4	111	76	75	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	28	36.8	104	77	75	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	37	105	71	79	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-10	36.8	127	86	55	95.9	181.7
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.2	124	89	58	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	7	37.1	122	87	60	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	14	36.8	121	82	72	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.8	130	87	68	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	36.5	114	86	72	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-6	36.2	150 (Mild)	85	69	81.5	177
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.5	150 (Mild)	82	71	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	7	36.6	145 (Mild)	79	69	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	14	36.4	139	83	68	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	28	36.8	130	83	63	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.9	122	79	83	83.3	174.5
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.3	120	75	99	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	9	36.4	123	77	82	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	15	36.5	109	76	94	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	30	36.4	112	67	96	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	37.3	136	81	80	72.2	158.1
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	37.2	113	77	82	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	37.2	128	71	80	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	36.2	132	71	78	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.6	119	73	79	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.8	138	78	56	64.7	166.5
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	36.3	109	66	66	.	.

Report Date: 02JUN2020  
 Data Cutoff Date: 25MAY2020

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	36.8	111	69	70	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	36.3	92	53	63	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.7	102	60	62	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.4	138	84	81	52	149
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	37	140	86	78	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	36.6	134	80	86	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	16	36.1	134	78	80	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	37	113	72	70	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.5	115	72	41 (Severe)	88.6	186
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	37	143 (Mild)	79	74	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	36.6	122	74	68	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	36.6	102	55	61	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	30	36.3	116	69	61	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.7	110	72	78	56.4	164.5

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.9	101	71	89	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	7	37.3	113	70	88	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	14	37.2	109	75	86	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	28	37.1	110	75	90	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.4	147 (Mild)	93 (Mild)	75	64.2	160.1
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.5	150 (Mild)	93 (Mild)	75	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	8	36.1	142 (Mild)	89	83	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	15	36.4	142 (Mild)	92 (Mild)	85	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	29	36.3	146 (Mild)	91 (Mild)	72	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-4	37.2	134	87	60	66.5	171
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.4	130	84	66	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	8	37	120	79	71	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	15	36.6	116	78	77	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	29	37.1	126	88	75	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-2	36.4	121	79	58	62	163.1
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	37.1	113	71	72	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	9	36.3	104	64	62	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	16	36.4	113	68	63	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	30	36.8	124	69	61	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-6	36.3	129	74	53 (Mild)	60.6	167.7
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.9	129	81	62	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	7	36.5	116	70	65	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	14	36.9	113	71	64	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	28	37.4	128	72	67	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.8	122	77	77	78.5	167.9
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.8	119	58	70	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	36.8	126	73	85	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	13	36.7	112	68	80	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.9	113	79	91	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	37.2	118	67	73	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	41	36.9	117	68	86	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	55	36.8	125	72	98	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.7	129	71	67	98.7	188
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	37.1	136	75	81	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	9	36.7	137	73	83	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	15	36.6	116	73	83	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.6	125	74	75	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	36.7	119	74	81	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	46					.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	55					.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.8	140	92 (Mild)	85	81.6	172.7
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.7	138	83	85	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	36.7	136	84	85	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	15	37	138	90	86	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.7	123	87	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	36	37.1	136	87	84	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	36.8	129	77	70	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	57	36.9	139	81	94	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-2	36.7	142 (Mild)	70	78	77.1	177.8
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	120	77	88	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	36.7	129	68	80	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	14	36.7	113	76	70	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	28	36.7	125	80	80	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	36.7	140	71	91	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	42	36.8	124	77	72	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	56	36.6	126	79	70	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-4	36.4	119	83	56	87	172.7
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.8	117	82	69	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	36.7	110	76	63	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	15	36.6	111	64	55	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.4	107	68	55	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	36	36.5	110	67	56	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	36.6	109	77	60	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-14	36.4	109	70	66	64.5	165.1
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.5	106	52	66	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	7	36.3	147 (Mild)	86	80	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	14	36.8	108	60	76	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.6	115	72	69	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	36	36.7	114	61	79	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-14	36.7	103	58	58	70.6	154.9



**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.6	118	57	68	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.6	104	56	59	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.7	100	67	74	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.9	112	58	61	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	36	36.8	113	56	61	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-13	36.8	116	71	68	74.1	162.6
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.9	117	62	76	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	37.2	110	63	79	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	14	36.8	112	69	85	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	28	37.1	112	61	73	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	37.1	112	65	70	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-1	36.9	115	67	69	82.9	167.6
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	36.8	100	58	79	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	7	36.8	112	61	75	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	.	9	36.7	119	71	77	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	14	36.9	114	69	70	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.8	111	68	72	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	36	35	36.8	115	56	62	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-1	36.8	142 (Mild)	72	66	67.8	167.6
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	36.9	118	64	75	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	37.1	138	70	65	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	37	123	61	69	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.8	118	59	70	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	36	36	36.7	129	65	70	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-5	36.6	124	78	59	71.1	167.6
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.6	120	84	61	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	8	36.6	140	78	76	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	15	36.8	139	80	60	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	29	37.1	132	79	57	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.8	140	80	85	89.8	180.3
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	36.9	150 (Mild)	76	68	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	36.8	140	78	88	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	36.7	110	75	68	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.8	141 (Mild)	87	97	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.6	150 (Mild)	92 (Mild)	68	68.7	175.3
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	36.6	146 (Mild)	92 (Mild)	64	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	36.5	148 (Mild)	80	69	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	36.6	140	85	72	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.7	130	92 (Mild)	68	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.9	134	90	60	50.5	152.4
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.6	140	92 (Mild)	69	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	8	37	139	68	79	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	15	36.8	153 (Moderate)	87	73	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	30	36.8	130	70	84	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.9	116	72	68	86	182.9
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	36.9	114	73	69	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	36.6	115	62	76	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	36.9	117	69	77	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.9	127	77	72	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-5	36.7	101	58	58	64.7	171.5
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.8	96	60	64	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	8	36.9	91	63	69	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	15	36.6	103	57	69	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	29	36.8	105	70	61	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.5	141 (Mild)	70	74	95.2	195.6
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.6	129	74	75	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	9	36.2	130	79	81	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	14	36.6	137	71	76	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	28	36.8	128	84	78	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-10	36.9	144 (Mild)	88	75	92.7	185.7
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.9	132	88	77	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	8	37.3	122	80	60	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	16	36.9	130	76	88	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	30	36.8	142 (Mild)	80	72	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	38	36.9	128	82	62	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	44	36.6	130	84	64	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	59	36.8	120	80	80	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-9	36.6	106	74	65	56.2	158.7
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	37.1	104	65	72	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	8	37.2	101	64	88	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	15	36.8	114	69	99	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	30	37.1	102	67	84	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	38	37.2	113	79	89	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	44	36.9	103	58	86	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	59	37	111	72	83	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-9	36.6	114	69	56	62.9	172.6
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	37	120	63	56	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	8	36.7	111	65	67	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	15	36.7	112	63	65	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	30	37	106	56	58	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	38	37.2	118	61	57	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	44	36.7	108	53	62	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	59	36.6	114	64	65	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-9	36.6	105	65	80	57.8	164.6

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.4	128	61	87	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	8	36.4	113	57	82	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	15	36.6	103	65	69	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	30	36.9	114	59	77	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	38	36.4	115	52	76	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	44	37.1	109	52	81	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	59	36.8	100	66	78	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-7	36.7	139	97 (Moderate)	73	83.4	162.6
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	37.1	137	80	94	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	7	37	122	79	64	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	14	37.1	131	83	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	37.1	133	76	82	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	37	127	79	70	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	42	36.8	125	71	64	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	59	36.6	122	84	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-7	36.8	103	55	73	54.2	163.1
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.8	103	55	70	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	7	36.9	105	52	67	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	14	37	101	62	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	37.1	97	54	65	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	37	36.8	115	64	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	36.9	96	54	79	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	59	36.9	108	56	76	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-14	36.5	117	61	61	72.2	166.1
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.9	103	61	66	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.9	110	68	60	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.6	108	70	67	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.4	109	71	69	.	.



**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.3	102	59	63	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	105	59	73	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	111	72	66	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-14	36.3	121	70	61	107.9	182
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	128	73	89	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.9	112	74	96	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.7	116	68	69	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	150 (Mild)	69	81	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.8	112	64	75	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.7	116	64	72	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	115	68	81	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-6	36.4	139	66	55	81.6	169.2
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	37.2	138	71	72	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	7	37.1	130	65	68	.	.

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	14	37.1	118	60	69	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.9	120	61	70	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	37	37.1	117	56	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	37.1	114	72	80	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	58	37.2	109	52	73	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-6	36.8	114	69	84	72.5	166.6
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	116	67	87	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	7	36.7	112	63	93	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	14	37	114	67	88	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.9	94	50	81	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	37	37.4	119	55	94	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	37	113	61	97	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	58	37.3	96	52	73	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-13	36.5	110	70	63	76.6	173.7

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	37.2	101	62	79	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	37	105	65	66	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.8	110	72	81	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	107	64	68	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.5	106	62	67	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	37	115	68	73	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	58	36.8	102	61	81	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-12	36.5	115	70	64	88.3	182.1
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.7	114	65	57	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	8					.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	17	36.7	133	76	62	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.7	125	69	56	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.6	114	65	55	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.9	126	61	55	.	.

Report Date: 02JUN2020  
 Data Cutoff Date: 25MAY2020

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	57	36.8	118	67	65	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-11	36.9	115	59	62	72.8	182.9
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	110	58	60	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	113	73	73	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.9	104	60	68	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.9	115	57	72	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.4	116	53	82	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.4	117	68	73	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	57	36.8	114	65	70	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-11	36.8	107	72	77	91.5	174.2
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.7	111	72	81	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.8	121	85	95	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.7	117	71	75	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.7	115	71	73	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	36	36.6	118	73	84	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	125	76	98	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	114	71	93	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-11	36.9	106	67	84	65.9	174.5
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	124	80	82	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.8	107	70	97	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	37.6	110	67	80	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.7	104	64	78	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	37.1	111	71	79	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	100	58	91	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	56	37.1	111	71	93	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-10	37.3	129	79	75	71.5	177.4
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.7	131	79	78	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	123	76	77	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.7	115	72	74	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	108	62	83	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.7	106	59	81	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.6	117	72	83	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	113	68	76	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-10	37.2	105	64	72	69.2	167.4
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	104	55	72	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.7	110	65	85	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	37.1	108	66	80	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	99	58	70	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.7	110	60	78	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	110	60	84	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	58	36.6	118	57	79	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-25	37.2	142 (Mild)	82	56	76.7	185.7

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	133	69	90	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.7	132	60	63	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	37	128	68	62	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	28	36.4	125	75	63	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	36.8	120	64	65	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	43	43	36.3	122	71	67	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-10	36.9	131	72	72	68.8	179.5
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	124	69	69	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	116	70	79	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	37	104	58	71	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	37.1	104	58	78	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.8	123	69	92	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.6	120	79	86	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	56	36.7	110	73	80	.	.

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-7	36.6	132	74	98	92.3	194.1
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.4	129	73	69	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	122	67	71	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.9	109	64	66	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.6	116	62	75	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.8	119	55	79	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.5	114	68	72	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	57	37.1	121	59	79	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-21	36.9	107	56	72	53	161
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	116	72	70	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.8	111	75	70	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	16	36.6	116	72	77	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	28	36.5	117	76	68	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	36.7	110	69	82	.	.



**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	43	43	36.6	122	68	95	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-25	37.2	136	96 (Moderate)	87	81.1	173.2
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	37	133	85	87	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	138	91 (Mild)	56	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	138	83	64	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	37.7	137	83	84	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	36	37.2	130	84	75	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-20	37	120	62	90	53.2	159.8
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	37.4	114	62	88	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	118	72	88	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	16	36.5	131	72	89	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	28					.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	36.7	111	55	84	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	43	43	36.7	122	72	82	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-19	37	127	66	77	75.6	176.2
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	37.4	120	69	99	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.8	131	75	90	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	16	37.1	116	67	86	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	28	37.1	130	65	83	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	37.1	129	67	74	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	43	43	37.1	123	75	71	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-24	36.9	142 (Mild)	85	53 (Mild)	80.1	167
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	37	124	68	75	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	131	75	74	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	109	71	62	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	37.1	126	73	62	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	37	37.1	137	81	65	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-23	36.7	136	82	71	83.9	179.3

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	139	86	72	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	37.1	139	82	69	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	131	74	71	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.9	118	66	77	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	37	37.3	124	76	71	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-23	36.4	102	61	65	52.1	152.7
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	98	54	63	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	94	52	67	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.4	98	53	52 (Mild)	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.7	85 (Mild)	49	55	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	37	36.5	85 (Mild)	49	61	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-20	36.9	114	55	71	55.1	157.7
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	107	63	68	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.6	114	65	66	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	113	65	83	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.8	116	61	77	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	37	37.1	105	59	75	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-16	36.7	109	69	76	87.6	173.2
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.7	110	68	81	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.7	112	78	72	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	15	36.5	120	78	65	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-16	36.9	131	60	58	47.4	153.9
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.3	145 (Mild)	70	57	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.6	149 (Mild)	68	53 (Mild)	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	16	36.7	140	70	58	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-16	37.1	122	77	71	84	179
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.6	128	77	74	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.8	112	72	73	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	15	36.7	113	68	71	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-16	37.1	143 (Mild)	66	75	62.5	171.7
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.8	141 (Mild)	76	68	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	37.1	129	68	70	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	15	36.7	140	76	67	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-13	37.1	112	73	74	83.5	174.9
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.9	136	79	72	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	37.1	130	84	80	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	16	36.9	134	75	78	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-21	36.4	121	69	55	83.7	169.1
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.8	109	57	62	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	9	36.6	115	55	62	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-13	36.9	126	84	77	78.3	171.1
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.6	148 (Mild)	92 (Mild)	62	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.9	128	87	89	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	16	36.7	136	85	94	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-13	36.8	124	65	86	73.8	180.1
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.9	135	81	82	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.5	124	66	75	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	16	36.7	120	74	71	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-14	36.9	112	56	78	67.4	152.5
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.4	122	58	66	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	9	36.5	103	54	65	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	15	16	36.9	109	67	71	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-14	37.1	117	68	71	53.3	163.6
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.6	120	69	68	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.6	128	73	69	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	16	36.4	122	68	65	.	.

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-14	37.2	125	68	74	78.3	164.6
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	37	139	63	79	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.9	117	62	63	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	16	36.8	114	59	77	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-20	36.9	143 (Mild)	78	73	60.7	156.9
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	37.3	145 (Mild)	75	72	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	37	148 (Mild)	75	73	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-12	36.7	146 (Mild)	70	53 (Mild)	80.8	178.2
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.8	119	64	62	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.6	136	66	56	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	15	36.9	129	71	58	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-12	36.8	122	67	68	68.4	162.8
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.5	117	58	72	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	9	36.5	128	69	65	.	.

**Appendix F (continued)**  
**Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	15	16	36.9	129	62	61	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-18	36.7	114	56	74	78.7	162.8
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	37.1	118	56	74	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	36.9	137	60	83	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-19	36.6	133	74	63	91.2	181.7
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.7	136	67	59	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	37.2	134	78	73	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-19	36.9	118	53	63	57.9	169.6
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.6	116	54	64	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	36.7	139	60	63	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-18	37.1	118	58	57	62.4	171
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.7	113	75	65	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	36.7	127	60	54 (Mild)	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-19	36.8	134	65	69	71.2	173.9



**Appendix F (continued)**  
**Vital Signs Listing**

<b>Subject ID</b>	<b>Vaccination Group</b>	<b>Planned Study Day</b>	<b>Actual Study Day</b>	<b>Temperature (°C)</b>	<b>Systolic Blood Pressure (mmHg)</b>	<b>Diastolic Blood Pressure (mmHg)</b>	<b>Heart Rate (beats/min)</b>	<b>Weight (kg)</b>	<b>Height (cm)</b>
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.6	119	58	60	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	36.8	132	70	57	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-17	37.2	144 (Mild)	83	78	80	165.4
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	37.1	132	71	75	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	36.9	142 (Mild)	74	78	.	.

**APPENDIX G1:  
Listing of Protocol Deviations**

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	2	Too few aliquots obtained	Protocol procedure/assessment	28	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	2	Too few aliquots obtained	Protocol procedure/assessment	28	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	3	Too few aliquots obtained	Protocol procedure/assessment	34	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	2	Required procedure done incorrectly	Protocol procedure/assessment	55	REDACTED	No	No	No	REDACTED	REDACTED

Report Date: 02JUN2020  
Data Cutoff Date: 25MAY2020

**Appendix G1 (continued)**  
**Listing of Protocol Deviations**

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	Missed visit/visit not conducted	Follow-up visit schedule	2	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Out of window visit	Follow-up visit schedule	46	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	2	Required procedure done incorrectly	Protocol procedure/assessment	46	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	3	Required procedure done incorrectly	Protocol procedure/assessment	55	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	Required procedure not conducted	Protocol procedure/assessment	7	REDACTED	Yes, unsolicited AE	No	No	REDACTED	REDACTED

**Appendix G1 (continued)**  
**Listing of Protocol Deviations**

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	Other: non-required lab tests performed	Protocol procedure/assessment	1	REDACTED	No	No	N/A	REDACTED	REDACTED
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	Required procedure done incorrectly	Protocol procedure/assessment	-14	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Other: breach of confidentiality	Protocol procedure/assessment	-4	REDACTED	No	No	N/A	REDACTED	REDACTED
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	Required procedure not conducted	Protocol procedure/assessment	8	REDACTED	No	No	N/A	REDACTED	REDACTED
REDACTED	25 mcg mRNA-1273 (18-55 years)	2	Other: V4 safety labs collected out of window	Protocol procedure/assessment	17	REDACTED	No	No	N/A	REDACTED	REDACTED
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	Required procedure done incorrectly	Treatment administration schedule	28	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	Required procedure done incorrectly	Protocol procedure/assessment	1	REDACTED	No	No	N/A	REDACTED	REDACTED

**APPENDIX G2:  
Listing of Non-Subject Deviations**

<b>Study Site</b>	<b>Deviation Number</b>	<b>Deviation</b>	<b>Deviation Category</b>	<b>Reason for Deviation</b>	<b>Deviation Affected Product Stability?</b>	<b>Deviation Resolution</b>	<b>Comments</b>
REDACTED	1	REDACTED	Protocol procedure/assessment	REDACTED	Yes	REDACTED	REDACTED

**APPENDIX H:  
Listing of Pregnancies**

**Table 1 – Maternal Information**

**No maternal information has been reported**

**Table 2 – Gravida and Para**

**No gravida and para have been reported.**

**Table 3 – Live Birth Outcomes**

**No live birth outcomes have been reported**

**Table 4 – Still Birth Outcomes**

**No maternal information has been reported**

**Table 5 – Spontaneous, Elective, or Therapeutic Abortion Outcomes**

**No spontaneous, elective, or therapeutic abortion outcomes have been reported**